<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_SRM_Chennai_Description skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:SRM Chennai/Description</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="menu_wrapper"><DIV class="collapsable_menu_control"> MENU ▤ </DIV><UL id="accordion" class="accordion"><LI class="menu_item"><A href="https://2016.igem.org/Team:SRM_Chennai">HOME </A></LI><LI class="menu_item"> TEAM
			</LI><LI><A href=" https://2016.igem.org/Team:SRM_Chennai/Team"> Team   </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Collaborations">★  Collaborations </A></LI></UL><LI class="menu_item"> PROJECT  
			</LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Description"> ★  Description </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Design"> ★ Design </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Experiments"> Experiments </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Proof"> ★ Proof of Concept </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Demonstrate"> ★ Demonstrate </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Results"> Results </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Notebook"> Notebook </A></LI><LI class="menu_item"> PARTS  
			</LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Parts">Parts </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Basic_Part"> ★ Basic Parts </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Composite_Part"> ★ Composite Parts </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Part_Collection"> ★ Part Collection </A></LI><LI class="menu_item"><A href="https://2016.igem.org/Team:SRM_Chennai/Safety"> SAFETY </A></LI><LI class="menu_item"><A href="https://2016.igem.org/Team:SRM_Chennai/Attributions">★  ATTRIBUTIONS </A></LI><LI class="menu_item"> HUMAN PRACTICES 
			</LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Human_Practices"> Human Practices </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/HP/Silver">★ Silver </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/HP/Gold">★ Gold </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Integrated_Practices"> ★ Integrated Practices </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Engagement">★ Engagement </A></LI><LI class="menu_item"> AWARDS 
			</LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Entrepreneurship"> ★ Entrepreneurship </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Hardware"> ★ Hardware </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Software">★ Software </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Measurement">★  Measurement </A></LI><LI><A href="https://2016.igem.org/Team:SRM_Chennai/Model">★ Model</A></LI></DIV><DIV class="content_wrapper"><DIV class="column full_size"><P>As students of Bio Engineering, to serve humanity in the medical field strike us at the drop of

a hat. In our project we optimize the detection of Cancer in a hand held

minimally invasive chip with an immobilized DNA that is complementary to MALAT 1 and

a biomarker called Biodipy.</P><H5>PROJECT MOTIVATION:</H5><P>When we conducted a survey on Cancer we were shocked that 80% of people in rural areas

think that cancer detection and cure, costs an arm and a leg. This motivated us to develop a

device that can detect cancer accurately and at the same time cost effective. Our personal

contact with the Cancer Institute gave us the necessary boost up to materialise our idea.</P><H5>BACKGROUND:</H5><P>MALAT 1 gene produces a precursor transcript from which a long non-coding RNA is

derived by RNase P cleavage of a tRNA-like small ncRNA (known as mascRNA) from its 3'

end. The resultant mature transcript lacks a canonical poly (A) tail but is instead stabilized by

a 3' triple helical structure. This transcript is retained in the nucleus where it is thought to

form molecular scaffolds for ribonucleoprotein complexes. It may act as a transcriptional

regulator for numerous genes, including some genes involved in cancer metastasis and cell

migration, and it is involved in cell cycle regulation. Its upregulation in multiple cancerous

tissues has been associated with the proliferation and metastasis of tumor cells.
</P><H5>HOW DID WE DO IT?</H5><P>We designed a microfluidic chip using PDMS material which contains complementary DNA of 22 base pairs and a fluoromarker called Biodipy. The MALAT 1 amplified using E.Coli is fed into the channels of the chip which produces fluorescence whose intensity is proportional to cancer stages. We developed an algorithm for the intensity range for different stages of cancer. 
</P></DIV><UL class="demo-3"><LI><FIGURE><FIGCAPTION><H2>Stomach_cancer</H2><P>Search on Google or Wikipedia to know more about this. Happy to Help!</P></FIGCAPTION></FIGURE></LI></UL><UL class="demo-3"><LI><FIGURE><FIGCAPTION><H2>Microfluidic_chip</H2><P>Search on Google or Wikipedia to know more about this. Happy to Help!</P></FIGCAPTION></FIGURE></LI></UL><UL class="demo-3"><LI><FIGURE><FIGCAPTION><H2>Malat1_igem</H2><P>Search on Google or Wikipedia to know more about this. Happy to Help!</P></FIGCAPTION></FIGURE></LI></UL><UL class="demo-3"><LI><FIGURE><FIGCAPTION><H2>Lung Cancer</H2><P>Search on Google or Wikipedia to know more about this. Happy to Help!</P></FIGCAPTION></FIGURE></LI></UL><UL class="demo-3"><LI><FIGURE><FIGCAPTION><H2>Liver Cancer</H2><P>Search on Google or Wikipedia to know more about this. Happy to Help!</P></FIGCAPTION></FIGURE></LI></UL><UL class="demo-3"><LI><FIGURE><FIGCAPTION><H2>Chip Bonding</H2><P>Search on Google or Wikipedia to know more about this. Happy to Help!</P></FIGCAPTION></FIGURE></LI></UL><DIV class="column half_size"><H5>References</H5><P><UL><LI>1.	Posttranscriptional silencing of the lncRNA MALAT1 by miR-217 inhibits the epithelial-mesenchymal transition via enhancer of zeste homolog 2 in the malignant transformation of HBE cells induced by cigarette smoke extract.
            Lu L, Luo F, Liu Y, Liu X, Shi L, Lu X, Liu Q.
</LI><LI>2.	Regulation of MALAT1 expression by TDP43 controls the migration and invasion of non-small cell lung cancer cells in vitro.
             Guo F, Jiao F, Song Z, Li S, Liu B, Yang H, Zhou Q, Li Z.
</LI><LI>3.	Sp1-mediated transcriptional regulation of MALAT1 plays a critical role in tumor.
              Li S, Wang Q, Qiang Q, Shan H, Shi M, Chen B, Zhao S, Yuan L.
</LI><LI>4.	Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer.
           Schmidt LH, Görlich D, Spieker T, Rohde C, Schuler M, Mohr M, Humberg J, Sauer                                                                                                         Marra A, Faldum A, Müller-Tidow C, 
</LI><LI>
5.	Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations.
Lopez-Ayllon BD, Moncho-Amor V, Abarrategi A, Ibañez de Cáceres I, Castro-Carpeño J, Belda-Iniesta C, Perona R, Sastre L.
&lt;\li&gt;

6.	Expression of the long non-coding RNAs MEG3, HOTAIR, and MALAT-1 in non-functioning pituitary adenomas and their relationship to tumor behavior.
Li Z, Li C, Liu C, Yu S, Zhang Y.
li
</LI><LI>
7.	Low SOX17 expression is a prognostic factor and drives transcriptional dysregulation and esophageal cancer progression.
Kuo IY, Wu CC, Chang JM, Huang YL, Lin CH, Yan JJ, Sheu BS, Lu PJ, Chang WL, Lai WW, Wang YC.
</LI><LI>
8.	The long noncoding MALAT-1 RNA indicates a poor prognosis in non-small cell lung cancer and induces migration and tumor growth.
       Schmidt LH, Spieker T, Koschmieder S, Schäffers S, Humberg J, Jungen D, Bulk E, Hascher A, Wittmer D, Marra A, Hillejan L, Wiebe K, Berdel WE, Wiewrodt R, Muller-Tidow C.
</LI><LI>
9.	[Non-coding RNA in malignant tumors. A new world of tumor biomarkers and target structures in cancer cells].
              Diederichs S.
</LI></UL></P></DIV><DIV class="column half_size"><H5>Inspiration</H5><P>See how other teams have described and presented their projects: </P><UL><LI><A href="https://2014.igem.org/Team:Imperial/Project"> Imperial</A></LI><LI><A href="https://2014.igem.org/Team:UC_Davis/Project_Overview"> UC Davis</A></LI><LI><A href="https://2014.igem.org/Team:SYSU-Software/Overview">SYSU Software</A></LI></UL></DIV></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>